Systems biology and its application to the understanding of neurological diseases

Annals of Neurology

Volumn 65, Issue 2, 2009, Pages 124-139

  Villoslada, Pablo ^a,d   Steinman, Lawrence ^b   Baranzini, Sergio E ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; RNA; THROMBIN INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; COMPREHENSION; CREUTZFELDT JAKOB DISEASE; DISEASE CLASSIFICATION; FUNCTIONAL GENOMICS; HEREDITARY ATAXIA; HUMAN; HUNTINGTON CHOREA; MOLECULAR BIOLOGY; MOLECULAR MODEL; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; NONLINEAR SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; RNA SPLICING; SEIZURE; SYSTEMS BIOLOGY;

ANIMALS; HUMANS; NERVOUS SYSTEM DISEASES; SYSTEMS BIOLOGY;

EID: 62549088294     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21634     Document Type: Article

References (97)

1. Ideker T, Galitski T, Hood L. A new approach to decoding life: systems biology. Annu Rev Genomics Hum Genet 2001;2: 343-372.
2. Kitano H. Systems biology: a brief overview. Science 2002;295: 1662-1664.
3. Rosenblueth A, Wiener N. The role of models in science. Philos Sci 1945;12:316-321.
4. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-715.
5. Baranzini SE. Systems-based medicine approaches to understand and treat complex diseases: the example of multiple sclerosis. Autoimmunity 2006;39:651-662.
6. Germain RN. The art of the probable: system control in the adaptive immune system. Science 2001;293:240-245.
7. Watts DJ, Strogatz SH. Collective dynamics of 'small-world' networks. Nature 1998;393:440-442.
8. Barabasi AL, Oltvai ZN. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004;5:101-113.
9. Bertalanffy LV. General system theory: foundations, development, applications. New York: George Braziller, 1976.
10. Glass L. Synchronization and rhythmic processes in physiology. Nature 2001;410:277-284.
11. Kitano H. Computational systems biology. Nature 2002;420: 206-210.
12. Joyce AR, Palsson BO. The model organism as a system: integrating 'omics' data sets. Nat Rev Mol Cell Biol 2006;7: 198-210.
13. Sauer U, Heinemann M, Zamboni N. Genetics. Getting closer to the whole picture. Science 2007;316:550 -551.
14. Wagner A, Fell DA. The small world inside large metabolic networks. Proc Biol Sci 2001:268:1803-1810.
15. Wagner A. Robustness and evolvability in living systems. Princeton, NJ: Princeton University Press, 2005.
16. Kitano H. Biological robustness. Nat Rev Genet 2004;5: 826-837.
17. Stelling J, Sauer U, Szallasi Z, et al. Robustness of cellular functions. Cell 2004;118:675-685.
18. Wiener N. Cybernetics. New York: Wiley, 1948.
19. Cannon W. Organization for physiological homeostasis. Physiol Rev 1929;9:397.
20. Kitano H. A robustness-based approach ro systems-oriented drug design. Nat Rev Drug Discov 2007;6:202-210.
21. Villoslada P, Oksenberg J. Neuroinformatics in clinical practice: are computers going to help neurological patients and their physicians? Future Neurol 2006;1:1-12.
22. Glimcher P. Decisions, uncertainty, and the brain: the science of neuroeconomics. Cambridge, MA: MIT Press, 2004.
23. De Schutter E. Why are computational neuroscience and systems biology so separate? PLoS Comput Biol 2008;4:e 1000078.
24. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004;430:631-639.
25. Dragunow M. The adult human brain in preclinical drug development. Nat Rev Drug Discov 2008;7:659-666.
26. Stokin GB, Lillo C, Falzone TL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005;307:1282-1288.
27. Adalbert R, Gilley J, Coleman MP. Abeta, tau and ApoE4 in Alzheimer's disease: the axonal connection. Trends Mol Med 2007;13:135-142.
28. Bartzokis G, Sultzer D, Lu PH, et al. Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease. Neurobiol Aging 2004;25:843-851.
29. Wyss-Cotay T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006;12: 1005-1015.
30. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neuro-degeneration. Trends Neurosci 2005;28:202-208.
31. Miller JA, Oldham MC, Geschwind DH. A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging. J Neurosci 2008;28:1410-1420.
32. Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature 2006;443:768-773.
33. Hauser SL, Oksenberg |R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneratton. Neuron 2006;52:61-76.
34. Han MH, Hwang S, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets in the coagulation cascade. Nature 2007;451:1076-1081.
35. Villoslada P, Genain CP. Role of nerve growth factor and other trophic factors in brain inflammation. Prog Brain Res 2004; 146:403-414.
36. Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8:500-508.
37. Myerowitz R, Lawson D, Mizukami H, et al. Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum Mol Genet 2002:11: 1343-1350.
38. Myerowitz R, Mizukami H, Richardson KL, et al. Global gene expression in a type 2 Gaucher disease brain. Mol Genet Metab 2004;83:288-296.
39. Yamaguchi A, Katsuyama K, Nagahama K, et al. Possible role of autoantibodies in the pathophysiology of GM2 gangliosidoses. J Clin Invest 2004;113:200-208.
40. Qi Y, Ge H. Modularity and dynamics of cellular networks. PLoS Comput Biol 2006;2:1502-1510.
41. Sauro HM. Modularity defined. Mol Syst Biol 2008;4: 166-167.
42. Ma'ayan A, Jenkins SL, Neves S, et al. Formation of regulatory patterns during signal propagation in a mammalian cellular network. Science 2005;309:1078-1083.
43. Alon U. Network motifs: theory and experimental approaches. Nat Rev Genet 2007;8:450-461.
44. Losick R, Desplan C. Stochasticity and cell fate science. 2008; 320:65-68.
45. Smolen P, Baxter DA, Byrne JH. Mathematical modeling of gene networks. Neuron 2000;26:567-580.
46. Goni J, Esteban FJ, Velez N, et al. A computational analysis of protein-protein interaction networks in neurodegenerarive diseases. BMC Syst Biol 2008;2:52.
47. Goh Kl, Cusick ME, Valle D, et al. The human disease network. Proc Natl Acad Sci USA 2007; 104:8685-8690.
48. Lu X, Jain VV, Finn PW, Perkins DL. Hubs in biological interaction networks exhibit low changes in expression in experimental asthma. Mol Syst Biol 2007;3:98.
49. Lira J, Hao T, Shaw C, et al. A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell 2006;125:801-814.
50. Campillos M, Kuhn M, Gavin AC, et al. Drug target identification using side-effect similarity. Science 2008;321:263--266.
51. Ishikawa K, Torn S, Tsunemi T, et al. An autosomal dominant cerebellar ataxia linked to chromosome 16q22.1 is associated with a single-nucleotide substitution in the 5' untranslated region of the gene encoding a protein with spectrin repeat and Rho guanine-nucleotide exchange-factor domains. Am J Hum Genet 2005;77:280-296.
52. Loscalzo J, Kohane l, Barabasi AL. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol 2007;3:124.
53. Hunt CA, Baranzini SE, Matthay MA, Park S. A framework and mechanistically focused, in silico method for enabling rational translational research. American Medical Informatics Association (AMIA) Summit on Translational Bioinformarics; 2008; San Francisco, CA.
54. Mackey MC, Glass L. Oscillation and chaos in physiological control systems. Science 1977;197:287-289.
55. Varela F, Lachaux JP, Rodriguez E, Martinerie J. The brainweb: phase synchronization and large-scale integration. Nat Rev Neurosci 2001;2:229-239.
56. McCormick DA. Are thalamocortical rhythms the Rosetta Stone of a subset of neurological disorders? Nar Med 1999;5: 1349--1351.
57. Bar-Yam Y. Dynamics of complex systems. Reading, MA: Addison-Wesley, 1997.
58. Milton J, Black D. Dynamic diseases in neurology and psychiatry. Chaos 1995;5:8-13.
59. Milton |G, Longtin A, Beuter A, et al. Complex dynamics and bifurcations in neurology. J Theor Biol 1989;138:129-147.
60. Lopes da Silva F, Blanes W, Kalitzin SN, et al. Epilepsies as dynamical diseases of brain systems: basic models of the transition between normal and epileptic activity. Epilepsia 2003; 44(suppl 12):72-83.
61. Hausdorff JM, Cudkowicz ME, Firrion R, et al. Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease. Mov Disord 1998;13:428-437.
62. Llinas RR, Ribary U, Jeanmonod D, et al. Thalamocortical dysrhythimia: a neurological and neuropsychiatric syndrome characterized by magnetoencephalography. Proc Natl Acad Sci USA 1999;96:15222-15227.
63. Pezard L, Nandrino JL, Renault B, et al. Depression as a dynamical disease. Biol Psychiatry 1996;39:991-999.
64. Vitek JL, Giroux M. Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia. Ann Neurol 2000;47:S131--S140.
65. Olanow CW, Brin MF, Obeso JA. The role of deep brain stimulation as a surgical treatment for Parkinson's disease. Neurology 2000;55:S60-S66.
66. Schapira API, Bezard E, Brorchie J, et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev- Drug Discov 2006;5:845- 854.
67. Eckert T, Tang C, Eidelberg D. Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 2007;6:926-932.
68. Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007; 130: 1834-1846.
69. Huang C, Mattis P, Tang C, et al. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neu-roimage 2007;34:714-723.
70. Asanuma K, Tang C, Ma Y, et al. Network modulation in the treatment of Parkinson's disease. Brain 2006; 129:2667 -2678.
71. Frohlich F, Bazhenov M, Sejnowski TJ, Pathological effect of homeostatic synaptic scaling on network dynamics in diseases of the correx. J Neurosci 2008;28:1709-1720.
72. Yu AJ, Dayan P. Uncertainty, neuromodularion, and attention. Neuron 2005;46:681-692.
73. Hasselmo ME. Neuromodulation: acetylcholine and memory consolidation. Trends Cogn Sci 1999;3:351-359.
74. Hasselmo ME, Giocomo LM. Cholinergic modulation of cortical function. J Mol Neurosci 2006;30:133-135.
75. Hardy J, Cai H, Cookson MR, et al. Genetics of Parkinson's disease and parkinsonism. Ann Neurol 2006;60:389-398.
76. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006;7:306-318.
77. Hauser MA, Li YJ, Takeuchi S, et al. Genomic convergence: identifying candidate genes for Parkinson's disease by combining serial analysis of gene expression and genetic linkage. Hum Mol Genet 2003;12:671-677.
78. Noureddine MA, Li YJ, van der Walt JM, et al. Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra. Mov Disord 2005:20:1299-1309.
79. Lesnick TG, Papapetropoulos S, Mash DC, et al. A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet 2007;3:e98.
80. Lesnick TG, Sorenson EJ, Ahlskog JE, er al. Beyond Parkinson disease: amyotrophic lateral sclerosis and the axon guidance pathway. PLoS ONE 2008;3:el449.
81. Khalili K, White MK, Lublin F, et al. Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 2007;68:985-990.
82. Gelinas DS, DaSilva K, Fenili D, et al. Immunotherapy for Alzheimer's disease. Proc Narl Acad Sci USA 2004; 101 (suppl 2): 14657-14662.
83. Araujo RP, Liotta LA, Petricoin EF. Proteins, drug Targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov 2007;6:871-880.
84. Butcher EC. Can cell systems biology rescue drug discovery? Nat Rev Drug Discov 2005;4:461-467.
85. Paiacios R, Goni J, Martinez-Forero I, et al. A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases. PLoS ONE 2007;2:el222.
86. Fernald GH, Knott S, Pachner A, et al. Genome-wide network analysis reveals die global properties of IFN-beta immediate transcriptional effects in humans. J Immunol 2007;178:5076-5085.
87. Materi W, Wishart DS. Computational systems biology in drug discovery and development: methods and applications. Drug Discov Today 2007;12:295-303.
88. Aradi I, Erdi P. Computational neuropharmacology: dynamical approaches in drug discovery. Trends Pharmacol Sci 2006;27: 240--243.
89. Baranzini SE, Bernard CC, Oksenberg JR. Modular transcriptional activity characterizes the initiation and progression of autoimmune encephalomyelitis. J Immunol 2005;174:7412-7422.
90. Woolfe F, Waxman SG, Hains BC. In silico modeling of axonal reconnecrion within a discrete fiber tract after spinal cord injury. J Neurotrauma 2007;24:421-432.
91. Yildirim MA, Goh Kl, Cusick ME, et al. Drug-target network. Nat Biotechnol 2007;25:1119-1126.
92. Danna EA, Nolan GP. Transcending the biomarker mindset: deciphering disease mechanisms at the single cell level. Curr Opin Chem Biol 2006;10:20-27.
93. Nicholson JK. Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol 2006;2:52.
94. Ergun A, Lawrence CA, Kohanski MA, et al. A network biology approach to prostate cancer. Mol Syst Biol 2007;3:82.
95. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007;13:1359-1362.
96. Corvol JC, Pellerier D, Henry RG, er al. Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci USA 2008; 105:11839-11844.
97. Fogel LJ. Biotechnology: concepts and applications. Englewood Cliffs, NJ: Prentice-Hall, 1963.